The latest price of veentuzumab/ennosumab in 2025

Enfortumab/Enfortumab is an antibody conjugate (ADC), mainly used for the treatment of advanced or metastatic urothelial cancer (bladder cancer), especially for patients who have received chemotherapy and immunotherapy and still have disease progression. Its unique mechanism of action is based on targeting the Nectin-4 protein on the surface of tumor cells and conjugating antibodies with cytotoxic small molecule drugs to achieve precise killing of cancer cells. The antibody part is responsible for recognizing tumor cells, and the drug part releases cytotoxicity after being taken up by cells, thereby destroying tumor cells and delaying disease progression. Compared with traditional chemotherapy drugs, venetuzumab is more targeted and causes relatively less damage to normal tissues, so it shows important clinical value in patients who have failed previous chemotherapy.

In clinical application, veentuzumab is mainly administered via intravenous injection. Doctors will develop an individualized treatment plan based on the patient's body surface area and tolerance, and also coordinate with monitoring indicators such as hematology and liver function to ensure efficacy and safety. Common side effects include fatigue, rash, hand-foot syndrome and mild gastrointestinal discomfort, but are generally controllable. Overseas clinical practices and guidelines emphasize that patients need to be followed up regularly during use to detect and deal with adverse reactions in a timely manner to ensure the safety of continued treatment.

In terms of price, the generic drug Vientuzumab for injection has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance payment system, so the specific price information is still not completely clear. Referring to overseas markets, the European version of Veentuzumab with a specification of 20mg is priced at more than RMB 7,000 per box, and a box of 30mg may be priced at more than RMB 10,000. The actual price will fluctuate due to differences in exchange rates and channels. At present, there are no generic drugs at home or abroad, which means that patients still need to consider the cost of the original drug in terms of economic burden and accessibility.

Reference: https://www.padcev.com/